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Rihard Trebše, MD, Eleftherios Tsiridis, MD, Leo Whiteside, MDQUESTION 1A: When can irrigation and debridement (I&D) be
considered?
Consensus: I&D may be performed for early postoperative infections
that occur within 3 months of index primary arthroplasty with less
than 3 weeks of symptoms.
Delegate Vote: Agree: 84%, Disagree: 13%, Abstain: 3% (Strong
Consensus)
QUESTION 1B: Can irrigation and debridement (I&D) be
considered for late hematogenous infections?
Consensus: I&D may be performed for patients with late hematog-
enous infection that occurred within 3 weeks of an inciting event or
with symptoms not longer than 3 weeks.
Delegate Vote: Agree: 88%, Disagree: 9%, Abstain: 3% (Strong
Consensus)
Justiﬁcation:
I&D is a viable option to consider for patients with early
postoperative or late hematogenous infections [1]. The rate of
success of I&D has been stated to be between 0 and 89% [2]. What
is known is that this procedure, performed for early infections or
late hematogenous infections, has a higher success rate in healthier
patients, infections with low virulence organisms, and in patients
with short period of symptoms [1,3–25]. If I&D is to be attempted,
it is imperative to ensure that the prostheses are well-ﬁxed and
well-positioned and there is a good soft tissue envelope to cover
the prosthesis.
QUESTION 2: What are the contraindications for I&D?
Consensus: The inability to close a wound or the presence of a sinus
tract are absolute contraindications to performing an I&D and
retention of the prosthesis. Another absolute contraindication is the
presence of loose prostheses.
Delegate Vote: Agree: 95%, Disagree: 4%, Abstain: 1% (Strong
Consensus)
Justiﬁcation:
The inability to close a wound is an absolute contraindication
for retention of the prosthesis. An open wound allows for0883-5403/2902-0017$36.00/0 – see front matter © 2014 Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.arth.2013.09.043contamination and colonization of the prosthesis and will result
in a chronic infection. Other relative contraindications include
infection with highly virulent organisms such as methicillin-
resistant Staphylococcus aureus (MRSA) [25,26] or polymicrobial
infections [27] (often as a result of the presence of a sinus) and in
patients with extensive comorbidities, in particular those with
immunocompromised status [13,28]. Marculescu et al found that
the presence of a sinus tract leads to an odds ratio of 2.84 for
failure of I&D [29].
QUESTION 3A: When performing an I&D for hematoma after TKA,
should the deep fascia be opened?
Consensus: The fascia/arthrotomy should always be opened in
patients with total knee arthroplasty (TKA) and hematoma formation.
Delegate Vote: Agree: 87%, Disagree: 8%, Abstain: 5% (Strong
Consensus)
QUESTION 3B: When performing an I&D for hematoma after THA,
should the deep fascia be opened?
Consensus: Aspiration of the joint, either prior to surgery or at the
time of I&D, should be performed. For patients with a clear fascial
defect or hematoma/ﬂuid deep to the fascia conﬁrmed by aspiration,
the fascia should be opened.
Delegate Vote: Agree: 87%, Disagree: 9%, Abstain: 4% (Strong
Consensus)
Justiﬁcation:
There is little to no guidance in the literature about what should be
donewhen a surgeon encounters a draining wound and/or hematoma
formation [18,30]. Although superﬁcial hematoma formation is not
infrequent, the consequences of missing a deep hematoma or
infection in a patient with a prosthesis can be dire [15]. Thus, it is
the opinion of this consensus group that appropriate investigations
should be performed to evaluate whether a presenting hematoma is
superﬁcial or if it extends to deeper layers. The fascia should be
opened and the deeper hematoma evacuated in patients in whom
there is a blood or ﬂuid collection deeper in the fascia. I&D is a
different procedure compared to reoperation done for evacuation of a
hematoma.
101C. Haasper et al. / The Journal of Arthroplasty 29 Suppl. 1 (2014) 100–103QUESTION 4: How should I&D be performed for PJI?
Consensus: An I&D of a prosthetic joint needs to be performed
meticulously and according to the detailed protocol provided. Brieﬂy
this includes:
- Preoperative optimization of the patient
- Good visualization and thorough debridement
- Obtaining multiple culture samples
- Copious irrigation (6–9 L) of the joint
- Explantation of the prosthesis if indicated.
Delegate Vote: Agree: 90%, Disagree: 6%, Abstain: 4% (Strong
Consensus)
Justiﬁcation:
The joint should be opened via the previously mentioned access
under aseptic conditions [30]. Brush and wash all surfaces with an
antiseptic solution. Copious irrigation using low-pressure pulse lavage
or bulb irrigation should be performed. Reports in trauma surgery
have raised concern regarding the use of high pressure lavage, which
may spread the infection deeper [31,32].
QUESTION 5: Should the modular part always be exchanged
during I&D?
Consensus: Yes. All modular components should be removed and
exchanged, if possible, during I&D.
Delegate Vote: Agree: 92%, Disagree: 8%, Abstain: 0% (Strong
Consensus)
Justiﬁcation:
There is little evidence in the literature regarding the role of
exchanging modular components. Although this practice results in
added expenses, prolongs the surgery, and could potentially result in
increased morbidity, in our opinion it is necessary in order to allow
access to parts of the joint that otherwise could not be accessed
without removing the modular components. The latter is particularly
true for TKA. Access to the posterior capsule to perform extensive
debridement is not possible without removal of the tibial polyethyl-
ene. In addition, removal of the modular components allows for
removal of “slime” from the undersurface of such components leading
to better reduction of bioburden. We therefore believe it is advisable
to remove and exchange modular components (if possible) in all
patients undergoing I&D [1,6,7,11,13,17,25,26,30,33,34].
Although removal of polyethylene is absolutely necessary for
through debridement, reinsertion of a “sterilized” component may
also be reasonable. In a study by Laffer et al [35] the polyethylene
modular component was removed and washed with antiseptic during
I&D of TKA. The authors suggest that this may be a reasonable option
to exchange of components, which carries additional cost.
QUESTION 6: Do useful classiﬁcation systems (such as the
Tsukayama classiﬁcation) exist that may guide a surgeon in
deciding on the appropriateness of an I&D?
Consensus: The available classiﬁcation system is inadequate in
guiding a surgeon in selecting the appropriate surgical intervention
for management of early PJI. There is a need for further studies to
identify risk factors for failure of I&D in patients with acute PJI.
Delegate Vote: Agree: 84%, Disagree: 5%, Abstain: 11% (Strong
Consensus)
Justiﬁcation:
There are numerous classiﬁcation systems for PJI. The Tsukayama
classiﬁcation has been used as a rough guide and basis for selectionof surgical treatment [17,36]. It deﬁnes an early infection as one
that occurs within one month of index arthroplasty and any
infection beyond this point as late. Acute hematogenous infection
is also included in this classiﬁcation system. The Zimmerli/Trampuz
classiﬁcation deﬁnes an early infection as one that occurs within
3 months of index surgery. Infections with onset between 3 and
24 months are delayed infections and those occurring N24 months
after index arthroplasty are classiﬁed as late [23]. These classiﬁca-
tion systems are useful in that they provide a description for
pathogenesis, with the theory being that early infections may be the
result of seeding during surgery, whereas late infections are likely
acquired by hematogenous spread. Another classiﬁcation proposed
by Senneville et al relies mostly on the duration of symptoms and
places less emphasis on the timing of index arthroplasty. Based on
this classiﬁcation, acute infection is one with less than one month of
symptoms and any infection with greater than one month of
symptom are considered late [37]. Less than 4 weeks of symptoms
is quite common according to Garvin et al [17,38,39]. The
classiﬁcation proposed by McPherson considers criteria other than
timing such as host factors and micro-organism factors, and looks at
periods of less than 3 weeks [40]. Recent data suggest that the
success of prosthesis retention depends on many factors other than
the time at which infection occurs [41,42]. Thus, the decision to
perform an I&D for a patient with infection must take into account
many other parameters including the host type, the virulence of the
infecting organism, and status of the soft tissues. Bioﬁlm is the key
factor for success or failure using irrigation and debridement
[30,43]. Only with further research may we be able to identify
factors that inﬂuence the outcome of surgical intervention for PJI in
general and I&D in particular.
QUESTION 7: Is I&D an emergency procedure or can the patient be
optimized prior to the procedure?
Consensus: No. I&D is not an emergency procedure in a patient
without generalized sepsis. All efforts should be made to optimize the
patients prior to surgical intervention.
Delegate Vote: Agree: 92%, Disagree: 6%, Abstain: 2% (Strong
Consensus)
Justiﬁcation:
Although many believe that a patient presenting with an acute
infection should undergo surgery as soon as possible, there is no
evidence to suggest that any delay in surgical intervention
adversely affects the outcome. What is known is that patients
with medical comorbidities that are not controlled may be at risk
for medical complications, some of which could prove to be fatal.
In addition, subjecting a patient to I&D without addressing an
underlying coagulopathy that could be the result of administration
of anticoagulants can result in the development of a further
hematoma with all its adverse effects. Thus, it is critical that
conditions such as uncontrolled hyperglycemia (N180 mg/ml),
severe anemia (Hb b10 mg/dL), coagulopathy, and other reversible
conditions are addressed prior to subjecting a patient to I&D. The
nutritional status of any patient undergoing reoperation should
also be checked and provisions implemented to reverse malnutri-
tion, if present.
QUESTION 8: Does arthroscopy have a role in I&D?
Consensus: Arthroscopy has no role in I&D of an infected prosthetic
joint.
Delegate Vote: Agree: 91%, Disagree: 7%, Abstain: 2% (Strong
Consensus)
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There are some published studies demonstrating that the outcome
of I&D is markedly worse when debridement was performed using
arthroscopy [6,35,44]. As mentioned above, one of the main factors
determining the success of surgical intervention for treatment of PJI is
the ability to perform through debridement and reduce bioburden.
Using arthroscopy the surgeon is not able to access all compartments
and parts of the joint; therefore, thorough debridement is unlikely to
be performed. However, there may be a diagnostic role for
arthroscopy in knee arthroplasty.
QUESTION 9: How many I&Ds are reasonable before implant
removal is considered?
Consensus: Following failure of one I&D, the surgeon should give
consideration to implant removal.
Delegate Vote: Agree: 94%, Disagree: 6%, Abstain: 0% (Strong
Consensus)
Justiﬁcation:
Although surgical intervention needs to be individualized for each
patient, it is unlikely that multiple I&D procedures can serve a patient
well in the long run. If several attempts at I&D fail to control infection
in a patient, consideration should be given to implant removal [13,45].
Mont et al found it reasonable to perform multiple debridements in
their series of 24 acute TKA infections [46]. On the other hand, failure
of a single I&D procedure is recommended to be a consideration for
implant removal [47]. Another study found that a need for a second
debridement is an independent risk factor for failure of treatment
[19]. In the absence of conclusive evidence, we recommend that no
multiple I&D procedures should be performed in patients with acute
PJI. However there is evidence to perform multiple I&Ds within a
speciﬁc protocol.
QUESTION 10: Should culture samples be taken during I&D? If so
how many and from where?
Consensus: Representative tissue and ﬂuid samples, between 3 and 6,
from the periprosthetic region should be taken during I&D.
Delegate Vote: Agree: 98%, Disagree: 2%, Abstain: 0% (Strong
Consensus)
Justiﬁcation:
Despite attempts, distinction between benign hematoma and
acute infectionmay not always be possible. Thus, during I&D of a joint,
tissue or ﬂuid samples should be sent for microbiological examina-
tion. The information obtained from culture can then be used to
determine the course of treatment for the patient. Five to 6 samples
should be taken from areas that macroscopically appear most
clinically infected to the surgeon. These should include the superﬁcial,
deep, and periprosthetic layers and the interfaces between modular
components. If deﬁnitive components are removed, the bone/
prosthetic interface should also be sampled. The samples should be
submitted for aerobic and anaerobic culture [48]. Some authors have
shown that antibiotic prophylaxis at the time of induction does not
alter the results of the microbiological cultures obtained during the
surgery and should not be withheld [49].
QUESTION 11: Should extended antibiotic treatment be given to
patients following I&D? If so, what are the indications, type of
antibiotic, dose and duration of treatment?
Consensus: No. Extended antibiotic should only be administered to
patients that meet the criteria for PJI (see workgroup 7). The type,dose and duration of antibiotic treatment for infected cases should be
determined in consultation with an ID specialist.
Delegate Vote: Agree: 75%, Disagree: 20%, Abstain: 5% (Strong
Consensus)
Justiﬁcation:
Patients subjected to I&D should be worked up appropriately for
infection, including ordering erythrocyte sedimentation rate, C-
reactive protein, aspiration of the joint (either prior to or during
surgery), and culture. These investigations allow the treating medical
team to determine if there is high likelihood of PJI. For patients who
have a high suspicion for PJI, extended antibiotic treatment should be
administered. For others with normal serological and synovial
parameters and no evidence of active infection during surgery,
antibiotic therapy may not be indicated.
QUESTION 12: Is there a role for intra-articular local antibiotic
treatment after I&D? If so, deﬁne indications.
Consensus: No. There is inadequate evidence to support administra-
tion of continuous intra-articular antibiotics for the treatment of PJI.
Delegate Vote: Agree: 89%, Disagree: 7%, Abstain: 4% (Strong
Consensus)
Justiﬁcation:
Although the concept of administering continuous intra-articu-
lar antibiotic appears logical in that it allows higher local
concentrations of antibiotics, this procedure requires further
evaluation. The practice of continuous intra-articular antibiotic
administration was introduced by Whiteside et al and has been
shown to be successful in a case series [50]. No multivariate
analyses have been performed to demonstrate that the practice of
intraarticular administration of antibiotics is an independent factor
enhancing success. It is likely that a combination of factors such as
meticulous surgical debridement may explain the high success rate
that was observed in that case series [4,51]. There are some
potential risks associated with this practice, including drug
reactions, added expense, need for an additional surgery (to
remove the Hickman catheter), and possibly development of
antibiotic resistance. The use of continuous intra-articular antibi-
otics for the treatment of chronic infection, with a reported success
rate of 94%, also deserves further evaluation [50]. Those and other
case series need to be further evaluated [52,53].
QUESTION 13: Is there a role for the use of resorbable antibiotic-
impregnated pellets (calcium sulfate, etc)? If so, deﬁne
indications for use.
Consensus: No. Currently there is no conclusive evidence that the use
of antibiotic-impregnated resorbable material improves the outcome
of surgical intervention for I&D.
Delegate Vote: Agree: 88%, Disagree: 6%, Abstain: 6% (Strong
Consensus)
Justiﬁcation:
A number of case series have evaluated the role of antibiotic-
impregnated resorbable material for treatment of PJI. Although initial
reports of these series have been encouraging, there are no
randomized, controlled studies to demonstrate that the use of these
materials enhances the outcome of surgical intervention [53]. In one
study evaluating the outcome of I&D in 34 patients in whom
resorbable gentamicin was utilized, a success rate of 73% was
described which appears to not be much higher than what one
would expect with conventional I&D [54].
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cost, which depending on the material can be substantial, local
reaction to the resorbable material has been described.
Calcium sulphate pellets have been shown to increase wound
exudates [55,56]. A possible cytotoxic effect of this material has also
been described. Newer material such as nanoparticle hydroxyapatite
has been described [57]. Future studies are desperately needed to
evaluate the role of resorbable antibiotic-impregnated material, as
currently no concrete evidence exists that could support their use.
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